S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
3 Value Stocks Too Small For Buffett’s Portfolio
Stock market today: Asian shares are mostly higher after another set of Wall St records
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
How major US stock indexes fared Thursday, 3/28/2024
MillerKnoll, Chemours fall; Verint Systems, RH rise, Thursday, 3/28/2024
Mark Zuckerberg Says This CEO Is the 'Taylor Swift of Tech'
NASDAQ:IMUX

Immunic (IMUX) Stock Price, News & Analysis

$1.32
+0.02 (+1.54%)
(As of 03/28/2024 ET)
Today's Range
$1.30
$1.34
50-Day Range
$1.14
$1.53
52-Week Range
$0.95
$3.11
Volume
215,951 shs
Average Volume
584,235 shs
Market Capitalization
$118.71 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Immunic MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
430.3% Upside
$7.00 Price Target
Short Interest
Healthy
2.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.29mentions of Immunic in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.00) to ($0.99) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.03 out of 5 stars

Medical Sector

613th out of 938 stocks

Pharmaceutical Preparations Industry

293rd out of 441 stocks

IMUX stock logo

About Immunic Stock (NASDAQ:IMUX)

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

IMUX Stock Price History

IMUX Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Your Money is Not Safe
Biden Deploys Phase 1 Fednow Digital Currency Discover how to legally "opt-out" of the digital dollar today. No matter what they say, it's not something that will help you. If you don't take the action steps shown below…
Immunic Inc (IMUX) Reports Year-End 2023 Financial Results
Immunic's Earnings Outlook
What's Going On With Immunic Stock?
See More Headlines
Receive IMUX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Immunic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/22/2024
Today
3/29/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMUX
Employees
77
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+430.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-93,610,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.64 per share

Miscellaneous

Free Float
87,501,000
Market Cap
$118.71 million
Optionable
Optionable
Beta
2.07
(Almost) Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Duane D. Nash J.D. (Age 53)
    M.B.A., M.D., Executive Chairman
    Comp: $433.4k
  • Dr. Daniel Vitt Ph.D. (Age 56)
    CEO, President & Director
    Comp: $728.4k
  • Mr. Glenn Whaley CPAMr. Glenn Whaley CPA (Age 56)
    Chief Financial Officer
    Comp: $522.21k
  • Dr. Andreas Muehler M.D. (Age 59)
    Ph.D., Chief Medical Officer
    Comp: $599.57k
  • Dr. Hella Kohlhof (Age 51)
    Chief Scientific Officer
  • Jessica Breu
    Head of Investor Relations & Communications
  • Mr. Inderpal Singh (Age 58)
    General Counsel
  • Mr. Patrick Walsh (Age 41)
    Chief Business Officer

IMUX Stock Analysis - Frequently Asked Questions

Should I buy or sell Immunic stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Immunic in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IMUX shares.
View IMUX analyst ratings
or view top-rated stocks.

What is Immunic's stock price target for 2024?

1 equities research analysts have issued twelve-month price objectives for Immunic's shares. Their IMUX share price targets range from $7.00 to $7.00. On average, they anticipate the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 430.3% from the stock's current price.
View analysts price targets for IMUX
or view top-rated stocks among Wall Street analysts.

How have IMUX shares performed in 2024?

Immunic's stock was trading at $1.50 at the beginning of the year. Since then, IMUX stock has decreased by 12.0% and is now trading at $1.32.
View the best growth stocks for 2024 here
.

Are investors shorting Immunic?

Immunic saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 2,470,000 shares, an increase of 11.3% from the February 29th total of 2,220,000 shares. Based on an average trading volume of 977,100 shares, the days-to-cover ratio is presently 2.5 days.
View Immunic's Short Interest
.

When is Immunic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our IMUX earnings forecast
.

How were Immunic's earnings last quarter?

Immunic, Inc. (NASDAQ:IMUX) announced its earnings results on Thursday, February, 22nd. The company reported ($0.48) earnings per share for the quarter, topping analysts' consensus estimates of ($0.51) by $0.03.

What other stocks do shareholders of Immunic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immunic investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Trevena (TRVN), VBI Vaccines (VBIV), Moderna (MRNA), CymaBay Therapeutics (CBAY), NIO (NIO), NVIDIA (NVDA), TG Therapeutics (TGTX) and

Who are Immunic's major shareholders?

Immunic's stock is owned by many different retail and institutional investors. Top institutional investors include Gratus Capital LLC (4.30%), Vanguard Group Inc. (3.75%), Vanguard Group Inc. (1.88%), Sierra Summit Advisors LLC (0.72%), Northern Trust Corp (0.36%) and Bridgeway Capital Management LLC (0.25%). Insiders that own company stock include Andreas Muehler, Daniel Vitt, Duane Nash, Glenn Whaley and Joerg Neermann.
View institutional ownership trends
.

How do I buy shares of Immunic?

Shares of IMUX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IMUX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners